Literature DB >> 10491308

Deguanylation of human immunodeficiency virus (HIV-1) RNA by recombinant pokeweed antiviral protein.

F Rajamohan1, I V Kurinov, T K Venkatachalam, F M Uckun.   

Abstract

Modeling studies, combined with the molecular docking of the trinucleotide GGG into the active site of the deadenylating RNA N-glycosidase pokeweed antiviral protein (PAP), indicated that a guanine base can fit into the active site pocket of PAP without disturbing its unique geometry and is sandwiched between residues Tyr(72) and Tyr(123) very much like an adenine base. The guanine base can form two specific hydrogen bonds with the active site residues Ser(121) and Val(73) and the attached negatively charged phosphate groups can entertain stabilizing electrostatic interactions with two clusters of positively charged patches on the PAP surface formed by Lys(210) and Arg(179) from one side and Arg(122) and Arg(135) from the other side of the active site. These observations prompted the hypothesis that the RNA depurinating activity of PAP may not be restricted to adenine residues and PAP should be capable of deguanylating ribosomal and viral RNA as well. This hypothesis was experimentally confirmed by direct demonstration that guanine base is released from both ribosomal and HIV-1 RNA after treatment with purified recombinant PAP using quantitative high performance liquid chromatography. Recombinant PAP released adenine and guanine residues at a 1:1 ratio from HIV-1 RNA and at an approximately 3:1 (adenine:guanine) ratio from Escherichia coli ribosomal RNA. At a concentration of 5 microM, recombinant PAP released 263 +/- 10 pmol of adenine and 100 +/- 11 pmol of guanine from 1 microgram of E. coli ribosomal RNA (16S + 23S) within 4 h of treatment. By comparison, 138 +/- 12 pmol of adenine and 143 +/- 10 pmol of guanine were released from 1 microgram of HIV-1 RNA under identical treatment conditions (5 microM recombinant PAP, 4 h treatment). The deguanylation of the ribosomal and viral RNA targets by recombinant PAP was concentration-dependent and is abolished by alanine substitutions of the catalytic active site residues Tyr(72) and Tyr(123). To our knowledge, these findings provide the first evidence that PAP can deguanylate both ribosomal and viral RNA. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491308     DOI: 10.1006/bbrc.1999.1335

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  A novel mechanism for inhibition of translation by pokeweed antiviral protein: depurination of the capped RNA template.

Authors:  K A Hudak; P Wang; N E Tumer
Journal:  RNA       Date:  2000-03       Impact factor: 4.942

Review 2.  The role of enzymatic activities of antiviral proteins from plants for action against plant pathogens.

Authors:  Nandlal Choudhary; M L Lodha; V K Baranwal
Journal:  3 Biotech       Date:  2020-11-04       Impact factor: 2.406

3.  Structure-based design and engineering of a nontoxic recombinant pokeweed antiviral protein with potent anti-human immunodeficiency virus activity.

Authors:  Fatih M Uckun; Francis Rajamohan; Sharon Pendergrass; Zahide Ozer; Barbara Waurzyniak; Chen Mao
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

4.  Inhibition of hepatitis B virus replication by pokeweed antiviral protein in vitro.

Authors:  Yong-Wen He; Chun-Xia Guo; Yan-Feng Pan; Cheng Peng; Zhi-Hong Weng
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

5.  Pokeweed antiviral protein binds to the cap structure of eukaryotic mRNA and depurinates the mRNA downstream of the cap.

Authors:  Katalin A Hudak; Joseph D Bauman; Nilgun E Tumer
Journal:  RNA       Date:  2002-09       Impact factor: 4.942

6.  CNS activity of Pokeweed anti-viral protein (PAP) in mice infected with lymphocytic choriomeningitis virus (LCMV).

Authors:  Fatih M Uckun; Larisa Rustamova; Alexei O Vassilev; Heather E Tibbles; Alexander S Petkevich
Journal:  BMC Infect Dis       Date:  2005-02-22       Impact factor: 3.090

Review 7.  Pokeweed antiviral protein, a ribosome inactivating protein: activity, inhibition and prospects.

Authors:  Artem V Domashevskiy; Dixie J Goss
Journal:  Toxins (Basel)       Date:  2015-01-28       Impact factor: 4.546

Review 8.  Medicinal plants: Treasure for antiviral drug discovery.

Authors:  Sofi Imtiyaz Ali; Wajid Mohammad Sheikh; Muzafar Ahmad Rather; Venugopalan Venkatesalu; Showkeen Muzamil Bashir; Showkat Ul Nabi
Journal:  Phytother Res       Date:  2021-02-16       Impact factor: 6.388

Review 9.  Potential "biopeptidal" therapeutics for severe respiratory syndrome coronaviruses: a review of antiviral peptides, viral mechanisms, and prospective needs.

Authors:  Tolulope Joshua Ashaolu; Asad Nawaz; Noman Walayat; Ibrahim Khalifa
Journal:  Appl Microbiol Biotechnol       Date:  2021-04-19       Impact factor: 4.813

10.  Structural analysis of a type 1 ribosome inactivating protein reveals multiple L‑asparagine‑N‑acetyl‑D‑glucosamine monosaccharide modifications: Implications for cytotoxicity.

Authors:  Tanis Hogg; Jameson T Mendel; Jonathan L Lavezo
Journal:  Mol Med Rep       Date:  2015-07-29       Impact factor: 2.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.